ARRB1 and plasma cell myeloma: Second, the dramatic reduction in PD-1 expression we observed suggests that ARRB1 inhibition could enhance the efficacy of PD-1/PD-L1 checkpoint inhibitors, which have shown limited success in multiple myeloma as monotherapy.